LRRC15 promotes osteogenic differentiation of mesenchymal stem cells by modulating p65 cytoplasmic/nuclear translocation

• DOI: 10.1186/s13287-018-0809-1
• Publication Date: 2018-03-09T08:43:54Z
• Authors: Yuejun Wang; Yunsong Liu; Min Zhang; Longwei Lv; Xiao Zhang; Ping Zhang; Yongsheng Zhou
• Keywords: RUNX2

Mesenchymal stem cells (MSCs) are a reliable resource for bone regeneration and tissue engineering, but the molecular mechanisms of differentiation remain unclear. The tumor antigen 15-leucine-rich repeat containing membrane protein (LRRC15) is transmembrane demonstrated to play important roles in cancer. However, little known about its role osteogenesis. This study was evaluate functions LRRC15 osteogenic MSCs. Osteogenic-induction treatment ovariectomized (OVX) model were performed investigate potential relationship between MSC A loss-of-function used explore MSCs vitro vivo. NF-κB pathway inhibitor BAY117082, siRNA, nucleocytoplasmic separation, ChIP assays clarify mechanism regulation. Our results first that expression upregulated upon induction, level significantly decreased OVX mice. Both in-vitro in-vivo experiments detected required osteogenesis Mechanistically, inhibited transcription factor signaling by affecting subcellular localization p65. Further studies indicated regulated p65-dependent manner. Taken together, our findings reveal an essential regulator through modulating p65 cytoplasmic/nuclear translocation, give novel hint MSC-mediated regeneration.